

OVERVIEW

PRESS RELEASES

EVENTS & PRESENTATIONS

CORPORATE GOVERNANCE

MANAGEMENT

BOARD OF DIRECTORS

COMMITTEE COMPOSITION

CONTACT THE BOARD

FINANCIAL INFORMATION

SEC FILINGS

ANNUAL REPORTS

QUARTERLY RESULTS

STOCK INFORMATION

HISTORIC STOCK LOOKUP

INVESTMENT CALCULATOR

ANALYST COVERAGE

INVESTOR FAQs

CONTACT US

EMAIL ALERTS



## INVESTOR RELATIONS

### Investor Relations

Melinta Therapeutics, Inc. is dedicated to saving lives threatened by the global public health crisis of bacterial infections, through the development and commercialization of novel antibiotics that provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use

in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this pipeline provides Melinta with the unique ability to provide doctors and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections.

## STOCK QUOTE


**Price**      **Change**      **High**

May 23, 2018 5:05 PM EDT

[VIEW DETAILS](#)

Copyright Nasdaq. Minimum 15 minutes delayed.

## STOCK CHART



## PRESS RELEASES

May 21, 2018 [Melinta Therapeutics Announces Proposed Offering of Common Stock](#)

May 11, 2018 [Melinta Therapeutics Launches New Antibiotic Stewardship Program to Combat Growing Threat of Antimicrobial Resistance](#)

May 08, 2018 [Melinta Therapeutics Reports First Quarter 2018 Financial Results](#)

## EVENTS & PRESENTATIONS

[FILTER](#)

[RESET](#)

May 08, 2018 [Melinta Therapeutics Q1 2018 Earnings Call](#)

[CLICK HERE FOR WEBCAST](#)

[Q1 2018 Earnings Presentation](#) 714.5 KB

Mar 27,  
2018

Melinta Therapeutics, Inc. at the Needham & Company's  
17th Annual Healthcare Conference

[CLICK HERE FOR WEBCAST](#)

Mar 13,  
2018

Melinta Therapeutics Q4 2017 Earnings Call

[CLICK HERE FOR WEBCAST](#)



梵

俊

宥